Iowa State Bank Sells 1,725 Shares of Johnson & Johnson (NYSE:JNJ)

Iowa State Bank reduced its stake in Johnson & Johnson (NYSE:JNJ) by 3.6% during the third quarter, Holdings Channel.com reports. The firm owned 45,736 shares of the company’s stock after selling 1,725 shares during the quarter. Johnson & Johnson accounts for approximately 1.5% of Iowa State Bank’s holdings, making the stock its 22nd largest position. Iowa State Bank’s holdings in Johnson & Johnson were worth $7,412,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Maltin Wealth Management Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter worth $212,000. West Coast Financial LLC grew its position in shares of Johnson & Johnson by 764.7% during the third quarter. West Coast Financial LLC now owns 64,553 shares of the company’s stock valued at $10,461,000 after purchasing an additional 57,088 shares in the last quarter. DLK Investment Management LLC grew its position in shares of Johnson & Johnson by 2.3% during the third quarter. DLK Investment Management LLC now owns 33,780 shares of the company’s stock valued at $5,474,000 after purchasing an additional 771 shares in the last quarter. Castle Rock Wealth Management LLC grew its position in shares of Johnson & Johnson by 0.8% during the third quarter. Castle Rock Wealth Management LLC now owns 12,689 shares of the company’s stock valued at $2,030,000 after purchasing an additional 106 shares in the last quarter. Finally, LVW Advisors LLC grew its position in shares of Johnson & Johnson by 9.8% during the third quarter. LVW Advisors LLC now owns 19,111 shares of the company’s stock valued at $3,097,000 after purchasing an additional 1,705 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $161.45 on Friday. The company has a 50 day moving average price of $162.59 and a 200-day moving average price of $154.49. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a market capitalization of $388.56 billion, a PE ratio of 10.07, a P/E/G ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the previous year, the firm posted $2.80 earnings per share. The company’s revenue was up 4.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.07%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Royal Bank of Canada increased their price target on shares of Johnson & Johnson from $175.00 to $178.00 and gave the company an “outperform” rating in a report on Tuesday. Morgan Stanley increased their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.43.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.